No significant differences were observed between V1 and V3 in overall survival (OS) or objective response rate (ORR).<h4>Conclusion</h4>EML4-ALK v3 may be an important negative prognostic factor for the efficacy of targeted therapy in ALK positive NSCLC. This evidence concerns the gene EML4 and non-small cell lung carcinoma.